Companies › Biotheus
1 active drug program in 9 registered trials: 5 Phase 2, 2 Phase 3, 2 Phase 1; Oncology; next expected readout Jan 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| PM8002 bispecific antibody targeting PD-L1 and VEGF | CD274, VEGFA, PDCD1LG2 | Phase 3 | SCLC; Triple Negative Breast Cancer(TNBC); NSCLC; Neuroendocrine Neoplasm … | Jan 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT05844150 | PM8002 | Phase 2 | SCLC | Oncology | May 2024 |
| NCT05756972 | PM8002 | Phase 2 | NSCLC | Oncology | Sep 2024 |
| NCT05879068 | PM8002 | Phase 2 | SCLC | Oncology | Apr 2025 |
| NCT05918445 | PM8002 | Phase 1 | Malignant Neoplasm | Oncology | Nov 2025 |
| NCT05918133 | PM8002 | Phase 1 | TNBC | Oncology | Oct 2026 |
| NCT05879055 | PM8002 | Phase 2 | Neuroendocrine Neoplasm | Oncology | Jan 2027 |
| NCT06616532 | PM8002 | Phase 3 | SCLC | Oncology | May 2027 |
| NCT07133750 | PM8002 | Phase 2 | CRC (Colorectal Cancer) | Oncology | May 2027 |
| NCT06419621 | PM8002 | Phase 3 | Triple Negative Breast Cancer(TNBC) | Oncology | Jul 2027 |
Roche AstraZeneca Pfizer Akeso Suzhou Suncadia Biopharmaceuticals Shanghai Henlius Biotech Amgen IO Biotech AP Biosciences Jiangsu Simcere Pharmaceutical
LaNova Medicines Zhejiang Quetzal Therapeutics Beijing Pearl Biotechnology Limited Liability Company Quercis Pharma ABX advanced biochemical compounds
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.